CRISPR trailblazers Zhang, Liu and Joung join forces to launch Beam with $87M and cutting-edge gene-editing tech
Three of the founders behind the high profile gene-editing company Editas are taking their scientific prowess to a new venture, launching a startup this week that expands on the pioneering CRISPR tech the entire space is built on.
The new company — called Beam Therapeutics — is stepping out Monday with $87 million in launch money. Investors are backing true trailblazers in gene editing, as Beam’s scientific founders include David Liu, now-serial entrepreneur Feng Zhang, and J Keith Joung. All three are scientific founders of Editas, the CRISPR company launched in 2013 that now garners a $1.7 billion market cap.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.